Alisha Wainwright

How would this be managed?

Would you say that the reason perhaps postpartum hemorrhaging happens a lot in lower and middle income countries is that due to the fact that a lot of women are giving birth at home and there is that time gap?

So how did you...

Bringing it back to the first women trial, how did you select the countries that were going to participate, and how did those countries' perspectives help shape how you designed the trial?

So tell me, what were the results from those first women trials?

Yeah.

So after the trial's results were announced, what new questions did it raise?

The woman trial proved TXA could save lives.

But proving something works is only the first step.

The next question they wanted to explore was how to make that treatment accessible.

And this became the basis for a new trial, I'm Woman.

And I spoke to Professor Nike Bello, the national coordinator for Nigeria for the women trials, who's been at the center of this work for over a decade, to give us an idea of why not just relying on intravenous injection directly into the veins might be the key to getting it to the women who need it the most.

It makes so much sense what Nike is saying to meet people where they are at.

Okay.

It's clear talking to Halima that making sure great science can change lives doesn't only depend on successful clinical trials.

It depends on power, policy, and whose voices can shape care, which is why advocacy is also a big part of the women trials.

As Nike told us, making TXA accessible depends on working with trusted community partners.

And one of those partners is Nigerian lawyer and civil rights activist Dr. Abiola Akiode Afolabi, who in 2002 founded the Women Advocates Research and Documentation Center, or Ward C, named after the ward where she gave birth.

Ward C is a key community and advocacy partner for the women trials, working to raise awareness of postpartum hemorrhage and the benefits of TXA.

Let's hear from Abiola about the work they're doing.